An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy

Jian Xu(University of California, Los Angeles), Yong‐Su Zhen(Chinese Academy of Medical Sciences & Peking Union Medical College), Liang Li(Shanghai Public Health Clinical Center), Xiujun Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Ruijuan Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Yi Li(Chongqing Institute of Green and Intelligent Technology), Shenghua Zhang(State Ethnic Affairs Commission)
Oncotarget
July 20, 2015
Cited by 22


Related Papers